In the TME, TIGIT is frequently co-expressed on tumor-infiltrating lymphocytes (TILs), particularly in concert with other immune checkpoint molecules such as PD-1, lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Here, LAG3 is linked to neoplasm.